SRI INTERNATIONAL TO #11

斯瑞国际到

• 批准号: 10723367
• 负责人: CAROL GREEN
• 金额: $ 9.54万
• 依托单位: SRI INTERNATIONAL
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-18 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10723367
• 关键词: Academia; Basic Science; Biotechnology; Chemistry; Clinic; Clinical Trials; Data; Development; Drug Formulations; Drug Kinetics; Funding; Goals; Grant; Human; Institutes; Institution; Intellectual Property; International; Lead; Licensing; Nervous system structure; Neurosciences Research; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Property Rights; Relapse; Research; Research Personnel; Research Support; Risk; Testing; Toxicology; Translating; United States National Institutes of Health; clinical candidate; drug development; drug discovery; experience; inhibitor; nervous system disorder; novel; novel therapeutics; programs; research clinical testing; small molecule; substance use; success

The NIH Blueprint Neurotherapeutics Network (BPN) is part of NIH Blueprint for Neuroscience Research, a collaborative framework that includes the NIH Office of the Director together with eleven NIH Institutes and Centers, that support research on the nervous system. The BPN was launched to enable neuroscientists in academia and biotechnology companies to develop new drugs for nervous system disorders. The BPN provides non-dilutive funding for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. Through the BPN program, investigators together with the NIH build a team and leverage drug discovery and development experts who can help them advance their basic research into human testing. This is accomplished through a combination of grant funding and access to a full range of NIH-funded drug discovery development CROs (medicinal chemistry, pharmacokinetics/ADME, toxicology, drug manufacturing, drug formulation and phase I clinical trials) and, most importantly, access to NIH funded consultants with extensive pharma experience spanning all drug development stages to help guide the team. A fundamental hallmark of the program is that the research institution retains the intellectual property rights. With a strong track record of success, the BPN program provides an excellent opportunity to translate basic and applied findings into novel clinical candidates and advance them to the clinic. The goal is to generate the required data to de-risk further funding for subsequent clinical trials, partnership, or out-licensing.

NIH蓝图神经治疗网络(BPN)是NIH神经科学研究蓝图的一部分，NIH神经科学研究蓝图是一个合作框架，包括NIH主任办公室以及支持神经系统研究的11个NIH研究所和中心。BPN的推出是为了使学术界和生物技术公司的神经科学家能够开发治疗神经系统疾病的新药。BPN为小分子药物的发现和开发提供非稀释性资金，从Hit-to-Lead化学到第一阶段临床测试。通过BPN计划，研究人员与NIH一起建立了一个团队，并利用药物发现和开发专家来帮助他们将基础研究推进到人体试验中。这是通过赠款资金和获得NIH资助的全方位药物发现开发CRO(药物化学、药代动力学/ADME、毒理学、药物制造、药物配方和I期临床试验)相结合的方式实现的，最重要的是，获得NIH资助的顾问，他们拥有跨越所有药物开发阶段的丰富制药经验，以帮助指导团队。该计划的一个基本标志是研究机构保留知识产权。凭借良好的成功记录，BPN计划提供了一个极好的机会，将基本和应用的发现转化为新的临床候选结果，并将其推向临床。其目标是生成所需的数据，以降低后续临床试验、合作伙伴关系或对外许可的进一步资金风险。